Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486360 | 0.84 | KDR (0.44) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL28217498 | 0.82 | LNPEP (0.58) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL28217499 | 0.82 | LNPEP (0.58) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL7703695 | 0.80 | LNPEP (0.53) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL22384242 | 0.80 | LNPEP (0.55) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL15037126 | 0.80 | LNPEP (0.55) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL17486458 | 0.79 | LY96 (0.44) | LNPEPERAP2ERAP1ROCK2LY96 | |
| SCHEMBL5921796 | 0.79 | GPR132 (0.59) | LNPEPERAP2ROCK2POLBMAPT | |
| SCHEMBL5921742 | 0.79 | GAA (0.64) | LNPEPERAP2ERAP1 | |
| SCHEMBL5921740 | 0.79 | GAA (0.64) | LNPEPERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | LNPEP 206/4885ERAP2 146/4885ERAP1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.